Your Followed Topics

Top 2 aarhus, denmark News Today

#1
Why diagnosing endometriosis often takes years
#1 out of 2
health7h ago

Why diagnosing endometriosis often takes years

  • New studies show endometriosis diagnosis often remains slow in primary care due to non-specific symptoms.
  • Researchers from Aarhus University led two studies in Denmark and the Faroe Islands under the FEMaLe project.
  • Doctors often recognise classic gynecological symptoms but miss non-specific signs like gastrointestinal issues.
  • Cyclical symptoms such as bloating and mood changes require systematic exploration to aid diagnosis.
  • Stigma around menstruation may influence help-seeking and clinician assessment.
  • Researchers identify diagnostic hierarchies that delay considering endometriosis.
  • Faroe Islands GPs call for closer collaboration and better referral pathways.
  • Recommendations include awareness of non-gynaecological symptoms and systematic symptom exploration.
  • The FEMaLe studies aim to shorten diagnostic delays and improve patient care pathways.
  • Experts say translating knowledge into clinical practice is the major challenge.
Vote 0
0
#2
Eton Pharmaceuticals doses first patient in ET-700 pilot study; topline results expected H2 2026
#2 out of 2100.00%
health3h ago

Eton Pharmaceuticals doses first patient in ET-700 pilot study; topline results expected H2 2026

  • ETON Pharma dosed the first patient in a double-blind pilot study of ET-700 for Wilson disease.
  • The study arms include ET-700, GALZIN, and placebo with a four-week treatment period.
  • Primary endpoint measures the change in hepatic copper uptake via 64Cu PET.
  • topline results are expected in the second half of 2026, potentially guiding a pivotal study.
  • The trial is conducted at Aarhus University with 36 healthy volunteers.
  • ET-700 is an extended‑release zinc acetate formulation under evaluation for Wilson disease.
  • A potential pivotal study could follow a positive pilot outcome in early 2027.
  • The study compares ET-700 with GALZIN and placebo to assess copper handling.
  • Topline results will be released in the second half of 2026.
  • The Financial SEC filing context is noted in the source summary.
Vote 0
0

Explore Your Interests

Unlimited Access
Personalized Feed
Full Experience
or
By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Explore Your Interests

Create an account and enjoy content that interests you with your personalized feed

Unlimited Access
Personalized Feed
Full Experience
or
By continuing, you agree to the Privacy Policy.. You also agree to receive our newsletters, you can opt-out any time.

Advertisement

Advertisement